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ABSTRACT 
 
Objective – The objective of this selective EBM review is to determine whether fixed-
combination prostaglandin analog/β-blocker therapy is safe and more effective than β-blocker 
monotherapy in the prevention of disease progression in adults with open-angle glaucoma. 
 
Study Design – Review of three English language randomized controlled trials published in 
2008 and 2010.   
 
Data sources – 3 randomized, controlled, double-blind trials comparing fixed-combination 
prostaglandin analog/β-blocker therapy to β-blocker monotherapy were found using Pubmed, 
Medline, and Cochrane databases.  
 
Outcome Measured – Disease progression/regression was assessed by post-baseline 
measurement of IOP during three follow-up visits throughout the trials.  The safety profile of 
each therapy was assessed by monitoring the number of adverse events reported by the 
participants or observed by the researchers.   
 
Results – All three studies demonstrated a significantly greater IOP reduction in participants 
treated with fixed combination prostaglandin analog/β-blocker therapy.  There was a 
significantly higher incidence of adverse events in the fixed combination group compared to the 
β-blocker monotherapy group; however, the fixed combination therapy was determined to be 
well-tolerated and superior over β-blocker monotherapy in the prevention of disease progression 
of open-angle glaucoma.       
 
Conclusions – Fixed combination prostaglandin analog/β-blocker therapy is safe and more 
effective than β-blocker monotherapy in the prevention of disease progression in adults with 
open-angle glaucoma.  The simple dosing schedule increases patient adherence compared to the 
more complex multi-drug regimen of the individual active components.  
 
Key Words – “open-angle glaucoma”, “combination therapy”, “prostaglandin analog”, “β-
blocker”  
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INTRODUCTION 
 Open-angle glaucoma (OAG) is a progressive disease characterized by insidious optic 
nerve damage that is commonly attributed to chronic intraocular pressure (IOP) elevation.1, 2   
In this type of glaucoma, IOP elevation is due to impaired drainage of aqueous fluid through the 
trabecular meshwork to the anterior chamber.  The exact mechanism of optic nerve damage by 
increased IOP is not yet understood.1   However, chronically elevated IOP results in optic nerve 
atrophy and enlargement of cup-to-disc ratio, consequently leading to visual field impairment 
progressing to irreversible vision loss.1,2  
 Early detection and prompt treatment of OAG is important within the practice of 
physician assistants since glaucoma is one of the leading causes of preventable blindness in the 
United States.1  Glaucoma affects more than two million Americans, accounting for an estimate 
of more than seven million office visits annually and $1.5 billion in direct healthcare cost.3  The 
prevalence of OAG is highest in diabetic patients and those with affected first-degree relatives.2  
Chronic IOP elevation in OAG is often asymptomatic until severe optic nerve damage has 
already occurred and permanent visual impairment has ensued.1,2  Therefore routine screening 
and early treatment of glaucoma are essential to halt the progression of the disease and to prevent 
irreversible visual loss.   
The treatment of OAG and blindness prevention can be achieved through pharmacologic 
agents aimed at reducing the IOP by decreasing aqueous fluid production or increasing aqueous 
fluid outflow.   Topical agents to suppress aqueous production include β-adrenergic blocking 
agents, alpha2-adrenergic agonists and carbonic anhydrase inhibitors.1,2   Agents that facilitate 
aqueous outflow include prostaglandin analogs and parasympathomimetic agents.  Laser 
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trabeculoplasty and glaucoma drainage surgery (trabeculectomy) are effective treatments for 
patients with inadequate response to the less invasive medical treatments.2  
Most patients with OAG respond well to medical treatments.  Nonetheless, there are still 
a large number of patients who require more than one topical agent for adequate IOP control. 
Prostaglandin analogs and β-blockers are often first-line agents and may be used concurrently to 
maximize IOP reduction due to their different mechanisms of action.2  However, the complexity 
of multi-drug regimen due to their different dosing schedule has made it a challenge to achieve 
satisfactory patient compliance.4,5 Therefore, many formulations of fixed-combination 
prostaglandin analog/β-blocker have been developed to enhance patient adherence to effectively 
treat and prevent the progression of glaucoma.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether fixed-combination 
prostaglandin analog/β-blocker therapy is safe and more effective than β-blocker monotherapy in 
the prevention of disease progression in adults with open-angle glaucoma. 
METHODS 
 All three studies included in this selective EBM review were randomized, double-blind, 
controlled trials.  The studied population included patients 18 years of age or older with open-
angle glaucoma or ocular hypertension.  The intervention used in the randomized controlled 
trials was fixed-combination prostaglandin analog/β-blocker therapy.  The treatment group was 
compared to a comparison group in which patients only received β-blocker monotherapy.   
 The article search was performed by the author of this selective review using PubMed, 
MEDLINE, and Cochrane databases with keywords “open-angle glaucoma”, “combination 
therapy”, “prostaglandin analog”, and “β-blocker”.  All three articles were published in English 
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in peer-reviewed journals.  Inclusion criteria for the search were randomized controlled trials and 
publication date between 1996 to present.  Exclusion criteria included systematic reviews, 
studies published prior to 1996, animal trials, and patients under 18 years of age.  Table 1 
outlined the demographics and characteristics of the included studies. 
Table 1.  Demographics and characteristics of included studies  
Study Type # Pts Age Inclusion Criteria Exclusion criteria W/D Interventions 
Higginbot
ham et al., 
2010  
RCT 394 > 18 - primary OAG or 
ocular HTN  
- Were receiving a β-
blocker for > 4 
weeks before 
screening.   
- mean IOP between 
26-36 mmHg  
- best-corrected visual 
acuity of 20/200 or 
better  
 
- Angle-closure glaucoma  
- hx of ocular procedure, 
inflammation w/i 3 
months or infection w/i 3 
wks before screening  
- use a systemic med 
known to affect IOP  
- contraindicated to β-
blocker 
- hypersensitivity to 
benzalkonium chloride  
- abnormal ocular 
conditions or 
uncontrolled systemic ds  
- women of childbearing 
potential w/o 
contraceptive methods or 
were pregnant/ nursing.  
 
56 Fixed-
combination 
latanoprost/ti
molol 
maleate vs. 
individual 
components 
Varma et 
al., 2010  
RCT 854 > 18 - primary OAG or 
ocular HTN  
- IOP ≥ 30 mmHg w/o 
ocular hypertensive 
meds or ≥ 25 mmHg 
with prior therapy 
 
- Not specified Not 
speci-
fied 
fixed 
combination  
latanoprost/ti
molol vs. 
individual 
components  
Brandt et 
al., 2008  
RCT 1061 > 18 - ocular HTN, OAG, 
or angle-closure 
glaucoma, and who 
required B/L ocular 
hypotensive tx 
- best corrected visual 
acuity of 20/200 or 
better O.U. 
- IOP > 24 mmHg 
 
- uncontrolled systemic ds, 
significant ocular 
irritation, or active ocular 
ds 
- contraindications to tx w/ 
study meds or their 
components 
- conditions that precluded 
accurate IOP readings 
- surgery w/i the past 3 
months 
- Concomitant ocular 
meds 
- Pregnant women or 
women of childbearing 
age w/o adequate 
contraceptive methods 
74 fixed 
combination 
Bimatoprost/t
imolol vs. 
individual 
components 
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OUTCOMES MEASURED 
The outcomes measured in all three RCTs include disease progression/regression and 
safety, which are both patient oriented evidence that mattered to the patients (POEMs).  Since 
OAG is an asymptomatic and insidious condition, disease progression was defined as an increase 
in IOP and disease regression as a reduction in IOP.  Lowering IOP halts optic nerve damage and 
prevents the progression of the disease to complete irreversible blindness.  Several studies have 
proposed that long-term large diurnal IOP fluctuation may be associated with disease 
progression.  Therefore Varna et al. also studied the effectiveness of fixed combination therapy 
on the reduction of diurnal IOP fluctuation.6  Higginbotham et al. and Brandt et al. investigated 
the safety profile of the intervention by assessing the number overall reported adverse event and 
ocular-related adverse events.4,5  
Brandt et al. and Higginbotham et al. scheduled follow-up IOP measurements at weeks 2, 
6, and 12;4,5 Varna et al. scheduled follow-up IOP measurements at weeks 2, 13, and 26.6  The 
IOP for each participant in all three studies was measured at three different times during each 
follow-up visit.  The diurnal IOP was the average of the three IOP measurements during each 
visit; and diurnal IOP fluctuation was the difference between the highest and lowest IOP of the 
three measurements taken at each visit.4,5,6  Varna et al. also converted the diurnal IOP 
fluctuation into dichotomous data as high (> 6 mmHg) and low (< 6 mmHg).6   
The safety profile of the intervention and comparison group was analyzed by monitoring 
the number of adverse events reported by the participants or observed by the researchers.  The 
severity of the adverse event and whether it was treatment-related were also assessed by the 
researchers.  Treatment-related adverse events were defined as those with onset or worsening 
after the initiation of the therapy.4,5   
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RESULTS 
 The study performed by Brandt et al. demonstrated statistically significant (p < 0.001)  
mean decreases from baseline IOP by the end of the trial of 8.1 + 3.3 mmHg and 6.4 + 3.5 
mmHg for the fixed combination therapy and β-blocker monotherapy, respectively. The efficacy 
of the treatment was measured as a mean diurnal reduction greater than 20% from baseline IOP 
and IOP of less than 18 mmHg.4  The percentage of participants achieving > 20% reduction from 
baseline IOP were 81.8% for the combination group and 49.8% for the β-blocker group; and the 
percentage of those with IOP < 18 mmHg were 39.2% and 12.2%, respectively (Table 2).4   The 
number needed to treat based on the data on IOP reduction is 4.   
Table 2.  The efficacy and safety of each treatment group reported by Brandt et al.   
 Efficacy Safety 
 > 20% reduction* < 18 mmHg*  # treatment-related AEs* 
Fixed combination 81.8 %   (436/533) 
39.2%   
(209/533) 
41.5 %   
(221/533) 
β-blocker 
monotherapy 
49.8 %   
(131/263) 
12.2 %   
(32/263) 
24.7 %   
(65/263) 
Number needed to treat: 4 
* Between-group p value: p < 0.001 
 
Higginbotham et al. reported statistically significant (p < 0.001) mean IOP differences 
(fixed combination – monotherapy) between the fixed combination group and the β-blocker 
group ranging from -3.79 mmHg to -2.14 mmHg.  The baseline diurnal IOP values were similar 
between the two treatment groups; however, the postbaseline diurnal IOP values at weeks 6 and 
12 were significantly lower in the fixed combination group compared to those of the β-blocker 
group (Table 3).5   Higginbotham et al. also reported a significantly higher percentage of 
participants in the fixed-combination group achieving a mean diurnal IOP of < 18 mmHg by the 
conclusion of the study, p <0.01.5   
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Table 3.  Mean diurnal IOP reported in Higginbotham et al. 
a Mean difference (95% CI):  - 2.83 mmHg (-3.54 to -2.11 mmHg); p < 0.001 
b Mean difference (95% CI): -3.02 mmHg (-3.79 to -2.24 mmHg); p < 0.001 
 
Varna et al. reported a statistically significant (p < 0.01) lower mean diurnal IOP in 
patients treated with the fixed combination compared to those treated with β-blocker 
monotherapy, 19.4 mmHg and 22.4 mmHg, respectively.  The differences from baseline to week 
26 were -2.9 mmHg for the fixed combination group and -0.7 mmHg for the β-blocker group; p 
< 0.01.6  The diurnal IOP fluctuation of participants in the fixed combination group was 
significantly lower in week 26 than was at baseline; p = 0.002; while there was a statistically 
insignificant increase in the diurnal IOP fluctuation of participants treated with β-blocker 
monotherapy; p = 0.097.6  The between-treatment difference was statistically significant (p < 
0.01) (Table 4).6   The dichotomized data of the diurnal IOP fluctuation also demonstrated 
significantly fewer patients with “high” ( > 6 mmHg) IOP fluctuation in the fixed combination 
group than in the monotherapy group; p = 0.003.  There was a reduction in the percentage of 
participants with “high” IOP fluctuation in the fixed combination group (13.3% at baseline vs. 
6.9% at week 26); whereas there was an insignificant increase in patients with “high” IOP 
fluctuation in the β-blocker monotherapy group (13.2% at baseline vs 14.9% at week 26; p = 
0.08) (Table 5).6   The number needed to treat based on the dichotomized diurnal IP fluctuation is 
14.   
   
 Mean diurnal IOP (SD), mmHg 
 Combination therapy β -blocker monotherapy 
Baseline 28.0 (2.2) 28.1 (2.3) 
Week 6 a 17.9 (3.3) 20.9 (3.7) 
Week 12 b 17.8 (3.5) 20.9 (3.5) 
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Table 4.  Mean diurnal IOP fluctuation at baseline and week 26 reported by Varna et al. 
 Mean diurnal IOP fluctuation (SD), mmHg 
 Fixed combination β -blocker monotherapy 
Baseline  3.7 (2.5) 3.4 (2.3) 
Week 26 3.0 (2.1) 3.7 (3.2) 
∆ (baseline - wk 26) a -0.68 (0.22) b 0.36 (0.22) c 
a between-treatment p value: p < 0.001 
b within-treatment p value: p = 0.002 
c within-treatment p value: p = 0.097 
 
Table 5. The number of participants with high (> 6 mmHg) and low (< 6 mmHg) mean 
diurnal IOP fluctuation as reported in Varna et al. 
 Mean diurnal IOP fluctuation  
  Fixed combination β -blocker monotherapy 
Baseline a     
High ( > 6 mmHg) 37 (13.3%) 28 (9.7%) 
Low ( < 6 mmHg) 241 (86.7%) 261 (90.3%) 
Week 26 b     
High ( > 6 mmHg) 19 (6.9%) 41 (14.4%) 
Low ( < 6 mmHg) 256 (93.1%) 243 (85.6%) 
Number needed to treat: 14 
a between-treatment p value: p = 1.078 
b between-treatment p value: p = 0.003 
The percentages of participants reporting an adverse event in Brandt et al. were 41% 
(221/533) for the fixed combination group and 24.7% (65/263) for the β-blocker group, p < 
0.001.  The percentage of participants in Higginbotham et al. reporting an adverse event were 
29.5% (49/134) for the fixed combination group and 23.7% (31/131) for the β-blocker group, 
with total numbers of reported adverse events of 58 and 48, respectively.  However, the 
statistical significance of this difference between the two treatment groups was not included in 
the data.  The number needed to harm was 6 for the Brandt et al. study and 17 for the 
Higginbotham et al. study (Table 6).   
Table 6.  Treatment-related adverse events reported in Brandt et al. and Higginbotham et al.  
  ERR CER RR RRI ARI NNH 
Brandt et al.  0.415 0.247 1.68 0.68 0.168 6 
Higginbotham et al. 0.295 0.237 1.24 0.245 0.058 17 
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 DISCUSSION 
 All three included studies demonstrated that fixed combination prostaglandin analog/β-
blocker is safe and significantly more effective than β-blocker monotherapy in the prevention of 
disease progression in patients with open-angle glaucoma.4,5,6 The two active ingredients of the 
fixed combination provided additive IOP reduction by affecting the aqueous level in two 
different mechanisms: decreased aqueous humor production by β-blocker and increased aqueous 
outflow by prostaglandin analog.1, 2  There was a significantly higher number of participants 
maintaining  a IOP of < 18 mmHg, which is the visual field progression threshold defined by the 
Advanced Glaucoma Intervention Study.5 Lowering IOP reduces optic nerve damage and 
therefore halts the progression of the disease to complete blindness.  The Collaborative Initial 
Glaucoma Treatment Study had suggested that a decrease in IOP of 35% or more could prevent 
the progression of optic nerve damage over a 5-year period.5 
 Brandt el al. and Higginbotham et al. reported greater numbers of treatment-related 
adverse events in participants treated with fixed combination therapy compared to those treated 
with β-blocker monotherapy.  Neither study reported serious treatment-related adverse event that 
resulted in discontinuation of the study.  The most common adverse event was conjunctival 
hyperemia.  Other reported adverse events were burning sensation in eye, eye pruritus and 
dryness, growth of eyelashes, foreign body sensation,…4,5  Brandt et al. suggested that the lower 
incidence of conjunctival hyperemia in patients treated with β-blocker monotherapy may be 
class-related.  The β2-antagonistic activity of β-blockers decreases nitric oxide production, 
consequently leading to less hyperemia.4  Additionally, the unopposed alpha1-agonistic effects of 
endogenous catecholamines due to β-blockade may also contribute to decreased hyperemia in the 
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β-blocker monotherapy group.4  Overall, the fixed combination of prostaglandin analog/β-
blocker is well-tolerated and safe for the prevention disease progression of open-angle glaucoma.  
 All three studies included in this review are randomized controlled trials with an adequate 
sample size.  However, one limitation of the study performed by Varna et al. is limited is that it 
was a posthoc analysis.6  Additionally, although fixed-combinations of prostaglandin analog/β-
blocker provide superior IOP reduction than β-blocker monotherapy, these formulations are not 
yet available in the United States.  Ganfort (bimatoprost 0.03% and timolol maleate 0.5%) is 
only available in certain countries, while Xalacom (latanoprost 0.005% and timolol maleate 
0.5%) and DuoTrav (travoprost 0.004% and timolol 0.5%) are only available in Canada.7 
CONCLUSION 
 Overall, fixed combination prostaglandin analog/β-blocker can be recommended for 
additional IOP reduction to help prevent disease progression in patients with open-angle 
glaucoma requiring more than one topical treatment.  The fixed combination therapy was found 
to be safe and more effective than β-blocker monotherapy.  Additionally, it is also well-tolerated; 
and its convenient simple dosing schedule increases patient adherence, maximizing long-term 
IOP reduction and therefore preventing the progression of the disease.  Future study is warranted 
to determine whether the fixed combination therapy is superior to multi-drug regimens of its 
individual active components in prevention of OAG disease progression.   
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